

# 1 **Biofilm Derived Oxylipin Mediated Autoimmune Response in Breast** 2 **Implant Subjects**

3 Imran Khan<sup>1</sup>, Robert E. Minto<sup>2</sup>, Christine Kelley-Patteson<sup>3</sup>, Bruce W. Van Natta<sup>3</sup>, Colby R.  
4 Neumann<sup>1</sup>, Lily J. Suh<sup>1</sup>, Kanhaiya Singh<sup>1</sup>, Mary Lester<sup>4</sup>, R Jason VonDerHaar<sup>4</sup>, Gayle M. Gordillo<sup>1</sup>,  
5 Aladdin H. Hassanein<sup>1</sup>, Chandan K. Sen<sup>1</sup>, Marshall E. Kadin<sup>5,6</sup>, Mithun Sinha<sup>1\*</sup>

6  
7 *<sup>1</sup>Indiana Center for Regenerative Medicine and Engineering, Department of Surgery, Division of*  
8 *Plastic Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA*

9 *<sup>2</sup>Department of Chemistry and Chemical Biology, Indiana University-Purdue University*  
10 *Indianapolis, Indianapolis, Indiana*

11 *<sup>3</sup>Meridian Plastic Surgeons, Indianapolis, Indiana*

12 *<sup>4</sup>Division of Plastic Surgery, Department of Surgery, Indiana University School of Medicine,*  
13 *Indianapolis, Indiana,*

14 *<sup>5</sup>Department of Dermatology, Roger Williams Medical Center, Boston University School of*  
15 *Medicine, Providence, Rhode Island, USA*

16 *<sup>6</sup>Warren Alpert School of Medicine, Brown University, Providence, Rhode Island*

17

18 \* Corresponding Author: Mithun Sinha, PhD; [mitsinha@iu.edu](mailto:mitsinha@iu.edu)

19 **Address:** 975 W Walnut St,  
20 Medical Research Library Building, Suite # 444A  
21 Indiana University School of Medicine  
22 Indianapolis, IN 46202.

23 Tel. 317 278 2713

24 Fax. 317 278 2708

25 **Short Title:** Biofilm mediated autoimmune response

## 26 **Abstract**

27 Over 10 million women worldwide have breast implants for breast cancer/prophylactic  
28 reconstruction or cosmetic augmentation. In recent years, a number of patients have described a  
29 constellation of symptoms that are believed to be related to their breast implants. This  
30 constellation of symptoms has been named Breast Implant Illness (BII). The symptoms described  
31 include chronic fatigue, joint pain, muscle pain and a host of other manifestations often associated  
32 with autoimmune illnesses. In this work, we report that bacterial biofilm is associated with BII. We  
33 postulate that the pathogenesis of BII is mediated *via* a host-pathogen interaction whereby the  
34 biofilm bacteria *Staphylococcus epidermidis* interacts with breast lipids to form the oxylipin 10-  
35 HOME. The oxylipin 10-HOME was found to activate CD4<sup>+</sup> T cells to Th1 subtype. An increased  
36 abundance of CD4<sup>+</sup>Th1 was observed in the breast tissue of BII subjects. The identification of a  
37 mechanism of immune activation associated with BII via a biofilm enabled pathway provides  
38 insight into the pathogenesis for implant-associated autoimmune symptoms.

39

40

41

42

43

44

45

## 46 Introduction

47 Breast implants were first introduced in 1962. Nearly 60 years later, their safety has continued to  
48 be controversial in the medical field, including a period of FDA-mandated restrictions on the use  
49 of silicone gel breast implants in the U.S. in the 1990s<sup>1, 2</sup>. Nearly 300,000 women have breast  
50 implant surgeries every year in the United States, for reasons including cosmetic augmentation,  
51 post-mastectomy breast reconstruction (breast cancer and prophylactic mastectomy), revision of  
52 prior augmentation/ reconstruction, and gender affirmation<sup>3</sup>. A subset of patients with breast  
53 implants have a myriad of nonspecific systemic symptoms<sup>4, 5</sup>. The symptoms described include  
54 fever, myalgias, chronic fatigue, arthralgias and a host of other manifestations often associated  
55 with autoimmune illnesses<sup>6-12</sup>. This constellation of symptoms related to implants has been named  
56 Breast Implant Illness (BII). The number of patients who opt for breast implant explantation due  
57 to complications including breast implant illness is over 30,000 annually<sup>3</sup>. Thus, BII is a growing  
58 concern to both patients and surgeons alike with more than 10 million women worldwide currently  
59 having breast implants<sup>6</sup>. Despite the increased concern regarding BII, existing scientific literature  
60 doesn't show a definite link between breast implants and autoimmune or connective tissue  
61 diseases. Some epidemiological studies have reported that women with silicone gel-filled implants  
62 were 8 times more likely to be diagnosed with Sjögren syndrome, an autoimmune disorder  
63 characterized by dry eyes and a dry mouth. Also, such subjects are 7 times more likely to be  
64 diagnosed with scleroderma, a group of autoimmune diseases that cause the skin and connective  
65 tissues to become hard and tighten, and nearly 6 times more likely to be diagnosed with  
66 rheumatoid arthritis<sup>8</sup>. Other studies have reported an association of autoimmune symptoms with  
67 breast implants<sup>7, 9-12</sup>. Symptoms have been documented to begin after placement of the implant  
68 and are often relieved by their explantation<sup>13, 14</sup>. This led patients and physicians to suspect that  
69 the breast implants are the likely cause<sup>13, 14</sup>. However, FDA mandated studies have found  
70 silicone gel breast implants to be safe<sup>15</sup>. Of note to this apparent contradiction is the fact that

71 these symptoms have been reported in subjects with other implants such as orthopedic  
72 arthroplasty which is typically comprised of titanium<sup>16-20</sup>. This indicates that the underlying cause  
73 of these conditions may be associated with factors other than the implant material. Therefore, it  
74 is important to decipher the underlying molecular mechanism associated with BII for a better  
75 understanding in the future of all implant-related illnesses with autoimmune manifestations.

76 This is the first in depth study to investigate the possible role of bacterial biofilm as a factor in the  
77 pathogenesis of BII through a patient-based study with a mechanistic pathway. We have identified  
78 a biofilm-derived oxylipin in increased abundance in BII subjects. The oxylipin led to activation of  
79 CD4<sup>+</sup> Th1 cells in an *in vitro* and *in vivo* mouse model suggesting a role in the establishment of  
80 an autoimmune response often observed to be associated with BII.

81

## 82 **Results**

### 83 **Bacterial Biofilm in Implant-Associated with BII**

84 The study included 68 patients. Forty-six patients with BII were analyzed. Subjects were  
85 diagnosed with BII using clinical parameters outlined in previous studies<sup>6-12</sup> (**Fig. 1A**) . As a part  
86 of the diagnosis, the patients were required to complete a questionnaire (**Supplementary Table**  
87 **1**). The questionnaire screened for the commonly reported symptoms associated with BII<sup>6-12</sup>.  
88 Implant, associated capsules and breast tissue were collected from these subjects (**Fig. 1B-C**)  
89 as described in methods. The mean age of BII patients was 44.0 years with mean duration of  
90 implant insertion of 11.51 years. Two groups were considered as controls. Control group I (non-  
91 BII, n=14) was comprised of patients with breast implants who didn't exhibit BII symptoms but  
92 went through explantation of the breast implant. The mean age of non-BII patients was 46.5 years.  
93 Control group II (normal tissue, n=8) was comprised of patients without an implant, whose breast  
94 tissue was removed as a clinically indicated surgical procedures e.g., (breast reduction surgery,

95 mammoplasty, contralateral procedures for reconstruction symmetry and mastopexy). The mean  
96 age of normal subjects was 26.8 years. The demographics of the subjects have been provided in  
97 **Supplementary Table 2.**

98 Bacterial biofilm was observed in implant-associated capsules through scanning electron  
99 microscopy (**Fig. 1D, Supplementary Fig. S1A**). Though biofilm was detected in the capsules of  
100 implants from both BII and non-BII patients, the abundance of biofilm was significantly more in  
101 the capsules of BII subjects as observed through wheat germ agglutinin (WGA) assay (**Fig 1E-F**).  
102 The microbiological culture analyses of the tissues resulted in no growth of bacterial colonies  
103 (data not shown). It has been reported that bacterial biofilms are difficult to detect through colony  
104 forming assays due to their subdued metabolism<sup>21, 22</sup>. Hence, in cases of bacterial biofilm, next  
105 generation sequencing (NGS) using variable region of bacterial 16S rRNA gene are employed to  
106 type bacteria and determine their abundance<sup>23</sup>. Diverse types of biofilm forming bacteria were  
107 observed associated with BII, non-BII and normal tissues (**Fig. 1G-I**) through next generation  
108 sequencing (NGS) of the 16S rRNA variable region. Most of the species identified were  
109 opportunistic bacteria associated with normal skin flora capable of forming biofilms. (**Fig. 1G-I**).  
110 Comparative analyses with the normal, non-BII and BII groups revealed an increased abundance  
111 of *Staphylococcus epidermidis* in BII (**Fig. 1J**). The other bacteria found in increased abundance  
112 in breast tissue was *Cutibacterium acnes*. Bivariate analysis using cross-tabulation was  
113 performed between presence of biofilm and the study groups. Using the Fisher's exact test,  
114 *Staphylococcus epidermidis* colonization was observed to be significantly higher ( $p < 0.001$ ) in the  
115 BII group (63.04%) compared to non-BII group (14.3%) and the normal group. Using exact logistic  
116 regression, the BII group was 9.8 times significantly more likely to have *S. epidermidis*  
117 colonization compared to the non-BII group ( $p = 0.003$ ). Similarly, when comparing with normal  
118 groups, the BII group was 17.4 times significantly more likely to have *S. epidermidis* ( $p = 0.0021$ ).  
119 *C. acnes* was not found to be associated (Fisher's exact  $p$ -value = 0.116) with the groups defined

120 in the study. However, though not significant, the BII group (80.4%) tended to show 4 times higher  
121 odds of colonization with *C.acnes* (Odds ratio from exact logistic regression=3.98 [95% CI: 0.32,  
122 26.10, p=0.1684]) compared to the normal (50.0%) group (**Fig. 1J, Supplementary Fig. S1B**).

### 123 **Increased Abundance of Biofilm Derived 10-HOME in BII Subjects**

124 The oxylipin (10)-hydroxy-(8E)-octadecenoic acid (10-HOME) is formed by the bacterial oxidation  
125 of oleic acid (**Fig. 2A**). The oxylipin 10-HOME has been reported to inhibit flagellum-driven  
126 swimming and swarming motilities and stimulate the formation of bacterial biofilms *in vitro*<sup>24</sup>. The  
127 oxylipin 10-HOME was synthesized in the laboratory (commercially not available) in natural  
128 isotopic abundance (light) isotope and deuterated (heavy) isotope forms. The former was used  
129 for biological experiments, whereas the later was used as a liquid chromatography-mass  
130 spectrometry (LC-MS) standard. The synthesized 10-HOME was validated through thin layer  
131 chromatography and NMR spectroscopy (**Supplementary Fig. S2A-B**).

132 Elevated levels of 10-HOME in implant-associated samples of BII compared to non-BII samples  
133 were observed through mass spectrometry (**Fig. 2B-D**). Positive correlation was observed  
134 between bacterial abundance and concentration of 10-HOME in BII subjects (**Fig. 2E**). Similar  
135 correlation was observed in BII subjects with *Staphylococcus epidermidis* (**Fig. 2F**). To determine  
136 if *S. epidermidis* was capable of synthesizing 10-HOME, it was cultured *in vitro* with oleic acid as  
137 a source of carbon. Formation of 10-HOME was detected using gas chromatography-mass  
138 spectrometry (**Fig. 2G**). Oxylipins have been reported to cause CD4<sup>+</sup> T cell activation<sup>25</sup>. Hence,  
139 we explored the role of CD4<sup>+</sup> T cells in BII.

### 140 **Abundance of CD4<sup>+</sup> Th1 Cells in Implant-Associated Tissue of BII Subjects**

141 Breast tissue associated with the implant of BII subjects showed increased presence of CD4<sup>+</sup>  
142 T-BET<sup>+</sup> T cells compared to that of non-BII breast tissue (**Fig. 3A**). T-BET transcription factor is  
143 critical in Th1 subtype determination<sup>26</sup>. Th1 cells are associated with an auto-immune response

144 in multiple illnesses including rheumatoid arthritis<sup>27</sup>. The CD4<sup>+</sup> Th1 cells associated with BII  
145 subjects also were CD36<sup>+</sup> (**Fig. 3B**). CD36 is a fatty acyl translocase<sup>28</sup>; its level is upregulated  
146 when uptake of fatty acid (normal or oxidized) is required. It is to be noted that BII is a systemic  
147 autoimmune manifestation. Hence, the peripheral blood of BII and non-BII subjects was analyzed  
148 for CD4<sup>+</sup> T cells (Th1, Th2, Th9 and Th22). Increased abundance of Th1 cells was observed in  
149 BII subjects (N=9) as measured through flow cytometry using CD183/CXCR3 (CD4<sup>+</sup> Th1 cell  
150 marker) (**Fig. 3C**). No significant difference was observed in the abundance of other Th subtypes  
151 Th2 (CD194), Th9 (CD196) and Th22 (CD196) between BII subjects and non-BII subjects  
152 (**Supplementary Fig. S3A-B**). The following human cell lines were used as positive control for  
153 validation of surface antigens. Mac2A for CD183, Mac2B for CD194<sup>29</sup> and TLBR1 for CD196<sup>30</sup>  
154 (**Supplementary Fig. S3C-E**). These results, however, don't definitively establish that 10-HOME  
155 led to CD4<sup>+</sup>Th1 cell induction or that 10-HOME can lead to CD36 upregulation. Thus, we studied  
156 the effect of 10-HOME on human primary naïve CD4<sup>+</sup> T cells.

157

### 158 **Oxylipin 10-HOME Polarizes Naïve CD4<sup>+</sup> T Cells to Th1 Subtype *in vitro***

159 In order to study the effect of 10-HOME on T cells, naïve CD4<sup>+</sup> T cells (isolated from human  
160 peripheral blood mononuclear cells) were treated with 100 µM 10-HOME for 48h. Increased CD36  
161 expression was observed in the 10-HOME treated CD4<sup>+</sup> T cells through immunocytochemistry  
162 (**Fig. 4A**), flow cytometry (**Fig. 4B**) and quantitative real time PCR (**Fig. 4H**) indicative of the 10-  
163 HOME mediated induction of CD36. Polarization to Th1 subtype occurred in the presence of 10-  
164 HOME as observed through immunocytochemistry (**Fig. 4C**), flow cytometry (**Fig. 4D**), and  
165 quantitative real time PCR (**Fig. 4I**). The CD4<sup>+</sup> cells exhibited increased expression of T-BET (a  
166 transcription factor activated during the polarization of naïve T cells to Th1 subtype<sup>26</sup>)(**Fig. 4C,**  
167 **4H, Supplementary Fig. 4A**), CD183/ CXCR3 (CD4<sup>+</sup> Th1 cell marker) (**Fig. 4D**), and Th1

168 secreted pro-inflammatory cytokine IFN- $\gamma$  through ELISA (**Fig. 4E**). The CD183<sup>+</sup> Th1 cells  
169 exhibited increased abundance of CD36 marker (**Supplementary Fig. 4B**). The other subtypes  
170 of CD4<sup>+</sup> T cells (Th2, Th9 and Th22) assayed didn't exhibit any statistically significant increase in  
171 abundance post 10-HOME treatment on naïve CD4<sup>+</sup> T cells. Th2 cells were assayed using  
172 surface marker CD194/CCR4 (**Supplementary Fig. 4C**), transcription factor GATA3  
173 (**Supplementary Fig. 4D**) and anti-inflammatory cytokines IL 4 and IL10 (**Fig. 4F-G**). Th9 and  
174 Th22 cells were assayed using surface marker CD196/CCR6 (**Supplementary Fig. 4E**).

175

### 176 **Elevated CD4<sup>+</sup> Th1 in Peripheral Blood of Mice Administered with 10-HOME**

177 To test if 10-HOME can induce Th1 cells *in vivo*, we administered 10-HOME into the abdominal  
178 mammary fat pad of mice (**Fig. 5A**) as described in the Methods. An increased abundance of  
179 CD4<sup>+</sup> Th1 cells was found in the murine blood 14 days post administration of 10-HOME (**Fig. 5B**).  
180 Other subtypes of CD4<sup>+</sup> T cells (Th2) didn't exhibit any statistically significant increase in  
181 abundance (**Fig. 5C**).

182

## 183 **Discussion**

184 Biofilm formation enables single-cell microbes to assume a temporary multicellular lifestyle, in  
185 which “group behavior” facilitates survival in adverse environments<sup>31</sup>. The transition from  
186 planktonic growth (associated with acute pathogenic infections) to biofilm occurs in response to  
187 environmental changes, and involves multiple regulatory networks thereby mediating the spatial  
188 and temporal reorganization of the bacterial cell<sup>31</sup>. Bacterial biofilms have been implicated to  
189 cause gastric cancer by *Helicobacter pylori*<sup>32</sup>, colon cancer<sup>33, 34</sup>, breast implant-associated  
190 anaplastic large cell lymphoma (BIA-ALCL) and chronic inflammation<sup>35-37</sup>. The factors that involve



191 interplay between host and pathogen are influenced by the micro-environmental niche where the  
192 bacteria reside<sup>22, 38, 39</sup>. Breast implants provided a conducive surface for the adherence and growth  
193 of bacterial biofilms<sup>40</sup>. The breast is a modified sweat gland, with multiple external opening from  
194 the mammary ducts *via* the nipple, providing a passage for microbes (normal skin flora) to the  
195 breast tissue. This concept has been supported by a report whereby researchers have shown the  
196 presence of microbes deep inside the breast tissue<sup>41</sup>. Many bacteria belonging to the normal  
197 microflora of the body have been reported to form bacterial biofilms<sup>42</sup>. *Pseudomonas*  
198 *aeruginosa*<sup>43, 44</sup>, *Staphylococcus aureus*<sup>45</sup> and *Ralstonia pickettii*<sup>40, 46</sup> are some of the common  
199 biofilm forming species associated with breast implants. The bacterial biofilms are difficult to  
200 detect since they have subdued metabolism and may not be detectable as CFUs in standard  
201 microbiological assays<sup>21, 22</sup>. They can be identified through structural assays like scanning  
202 electron microscopy (SEM)<sup>22, 47</sup> and genetic assays (e.g., 16S rRNA sequencing)<sup>48</sup>. The  
203 observation in this study of increased abundance of bacterial biofilm comprised of *Staphylococcus*  
204 *epidermidis* associated with implant-associated tissue of BII patients relative to controls was thus  
205 critical in understanding to the potential pathology of BII. It is to be noted that while this study was  
206 being performed, anecdotal evidence of *S.epidermidis* with BII was reported by Mark *et al*<sup>49</sup> .

207 The oxidation of fatty acids is one of the main biochemical reactions in the synthesis of lipid  
208 mediators. The oxygenation of unsaturated fatty acids leads to the formation of oxylipins, although  
209 free fatty acids are not readily available as they are found as triglycerides. The action of bacterial  
210 lipases, such as dioxygenases (DOX) and lipoxygenases (LOX) on breast adipose result in the  
211 availability of free fatty acids. When oleic acid is used as a bacterial substrate, it is oxidized to  
212 form 10-HOME. The unique adipose tissue found in breast tissue is rich in oleic acid containing  
213 lipids<sup>50, 51</sup>. The oxylipin 10-HOME has been reported to promote bacterial biofilms *in vitro*<sup>24</sup>. The  
214 increased abundance of 10-HOME in our study associated with breast tissues of BII subjects thus

215 provides evidence that breast microflora may interact with breast lipids promoting the formation  
216 of bacterial biofilms.

217 Oxylipins are also known to be immune-modulatory. It has been reported that 12,13 DiHOME  
218 derived from oxidation of linoleic acid led to the reduction of regulatory T cells (Tregs), impeded  
219 immune tolerance and promoted childhood atopy and asthma<sup>25</sup>. Elevated levels of 10-HOME  
220 formed due to bacterial biofilms could lead to immune cell activation. Reports suggest that CD4<sup>+</sup>  
221 T cells are activated due to the persistent presence of a bacterial biofilm<sup>52, 53</sup>. CD4<sup>+</sup> T cells play  
222 an important role in the pathogenesis of chronic systemic inflammatory autoimmune diseases  
223 such as multiple sclerosis, diabetes and rheumatoid arthritis<sup>54-56</sup>. CD4<sup>+</sup> T cells can be divided into  
224 Th1, Th2, Th9, Th17 and Th22 subsets based upon the cytokines they produce. In chronic  
225 inflammatory systemic autoimmune diseases such as diabetes, multiple sclerosis and rheumatoid  
226 arthritis, Th1 cells were found to be involved<sup>57</sup>. It is to be noted that many of the symptoms of BII  
227 patients were similar to rheumatoid arthritis and multiple sclerosis<sup>8</sup>. Th1 cells trigger delayed type  
228 hypersensitivity (DTH) reactions (which are mostly mediated by macrophages) and  
229 immunoglobulin class switch towards IgG2a<sup>55, 56</sup>.

230 Oxidized lipids have been associated with pain and inflammatory conditions<sup>58</sup>. Pain reported as  
231 arthralgia and myalgia are common in BII. We identified increased presence of CD4<sup>+</sup> Th1 cells  
232 in the breast tissue and peripheral blood of BII subjects. Findings of this study demonstrate that  
233 10-HOME was capable of polarizing naïve CD4<sup>+</sup> T cells towards Th1 subtype *in vitro*. Increased  
234 abundance of transcription factor T-BET required for Th1 fate was identified post 10-HOME  
235 treatment. The polarization to Th1 subtype was also supported by the observation of increased  
236 expression of pro-inflammatory cytokine IFN- $\gamma$  secreted by Th1 cells. Systemic analyses in our  
237 study didn't revealed polarization towards Th2, Th9 and Th22 subtypes. It is to be noted that the  
238 current work does not rule out the polarization of naïve CD4<sup>+</sup> T cells to Th17 subtype upon

239 treatment with 10-HOME. Th17 subtype has been also reported to be associated with auto-  
240 immune syndrome<sup>59</sup>.

241 To correlate the association of 10-HOME with activation of CD4<sup>+</sup> T cells *in vivo*, mice were  
242 administered with 10-HOME in their mammary fat pad. An increased abundance of CD4<sup>+</sup> Th1  
243 cells in peripheral circulation in 10-HOME administered mice was observed. These observations  
244 also help to explain the increased abundance CD4<sup>+</sup> Th1 in the BII subjects.

245 Taken together, we investigated the biofilm hypothesis of breast implant illness through a host-  
246 pathogen interaction. The breast microenvironment led to formation of biofilm derived 10-HOME  
247 from host oleic acid. The 10-HOME thus formed led to activation of CD4<sup>+</sup> Th1 cells *in vitro* and *in*  
248 *vivo*. The study provides the first evidence of a possible link of biofilm derived 10-HOME inducing  
249 an autoimmune response in patients with BII. Additionally, in light of reports of biofilm association  
250 with metal implants such as orthopedic arthroplasty, this study provides an explanation of  
251 autoimmune responses reported using those metal implants<sup>16-20</sup>. The findings of this study  
252 suggest that management of biofilm can help to increase the safety and long-term use of implants.  
253 Further research needs to be conducted to elucidate if other biofilm forming bacterial species are  
254 involved in the pathogenesis of BII. Also, more investigation is warranted to decipher the pathway  
255 leading to the onset of BII post-biofilm formation and the involvement of other biofilm derived  
256 metabolites.

257

## 258 **Materials and Methods**

259 **Human subjects.** Subjects participating in the study were patients diagnosed with BII.  
260 Demographic characteristics of patients presented in (**Supplementary Table 2**). All human

261 studies were approved by The Indiana University School of Medicine Institutional Review Board.

262 Declaration of Helsinki protocols was followed, and patients gave their written informed consent.

263 **Animals.** All animal (mice) experiments were approved by the Indiana University School of  
264 Medicine Institutional Animal Care and Use Committee (SoM-IACUC) under protocol 19102 -  
265 Murine model of breast implant diseases. Animals were housed under a 12-h light–dark cycle with  
266 food and water *ad libitum*.

267 **Bacterial strains.** Staphylococcus epidermidis (Winslow and Winslow) Evans (ATCC® 35984™)  
268 were grown on tryptic soy agar plate at 37°C.

269 **Scanning Electron Microscope Imaging.** The samples were collected in glutaraldehyde fixation  
270 buffer, dehydrated with graded ethanol, and treated with hexamethyldisilazane (HMDS, Ted Pella  
271 Inc.) and left overnight for drying<sup>22, 38</sup>. Before scanning, samples were mounted and coated with  
272 gold. Samples were imaged with FEI™ NOVA nanoSEM scanning electron microscope (FEI™,  
273 Hillsboro, OR) equipped with a field-emission gun electron source.

274 **Wheat-germ agglutinin (WGA) staining.** Paraffin embedded capsules surrounding the implant  
275 were sectioned on the slide. Wheat Germ Agglutinin, Alexa Fluor™ 488 Conjugate (Invitrogen)  
276 stock solution (1mg/ml) was diluted in PBS. The sections were stained with Wheat Germ  
277 Agglutinin (dilution 1:200) for 10 mins<sup>60</sup>. The slides were then mounted and imaged on a Zeiss  
278 LSM 880 microscope equipped with the AIRYscan detector.

279 **NGS sequencing for 16S rRNA.** Microbial DNA in each sample were sequenced by MicrogenDx  
280 Inc using the Illumina MiSeq sequencer. Forward and reverse primers were used to detect and  
281 amplify the target sequence, for 16S gene in bacteria. The samples are differentiated from each  
282 other when run on the MiSeq sequencer by a "tag," a unique identifying sequence attached to the  
283 forward and reverse primers implemented when the targeted sequence is amplified using PCR.  
284 Following PCR, purification of the pooled DNA was done by removing small fragments using both

285 Agencourt Ampure beads and Qiagen Minelute kit. The DNA was quantified and prepared for  
286 sequencing. Finally, the DNA library was run on the MiSeq sequencer. The sequencing reads  
287 were analyzed for quality and length during the data analysis. The data analysis pipeline  
288 consisted of two major stages, the denoising and chimera detection stage and the microbial  
289 diversity analysis stage. During the denoising and chimera detection stage, denoising was  
290 performed using various techniques to remove short sequences, singleton sequences, and noisy  
291 reads. With the low-quality reads removed, chimera detection was performed to aid in the removal  
292 of chimeric sequences. The high-quality sequencing reads of the variable region of 16S rRNA  
293 were compared to curated database of MicrogenDx. The database is comprised of 18500 unique  
294 bacteria.

295 **Synthesis of 10-HOME.** For the synthesis of 10-HOME, a convergent Horner-Wadsworth-  
296 Emmons approach was employed. Indiana University has filed a provisional patent application  
297 (Application # 63/107,626) on behalf of REM, IK and MS relating to the methods and synthesis of  
298 10-HOME and its deuterated 17,17,18,18,18 d<sub>5</sub> analog to be used as analytical standards.

299 **Primary T-cell isolation.** Naïve CD4<sup>+</sup> T cells were isolated from peripheral blood mononuclear  
300 cells (PBMC). Briefly, PBMCs were isolated by Ficoll-Paque PLUS density gradient  
301 sedimentation. Naïve CD4<sup>+</sup> T cells were then enriched using immunomagnetic, column-free,  
302 negative selection (Naïve CD4 T cell isolation kit, Miltenyi Biotec)<sup>61</sup>. Unwanted cells (CD8, CD14,  
303 CD15, CD16, CD19, CD25, CD34, CD36, CD45RO, CD56, CD123, TCRγ/δ, HLA-DR, and  
304 CD235a (Glycophorin A)) were removed using antibody complexes recognizing non-naïve CD4  
305 T cells and dextran-coated magnetic particles.

306 **Primary CD4<sup>+</sup> T cell culture and 10-HOME treatment.** Primary CD4<sup>+</sup> T cells were cultured under  
307 standard conditions at 37°C in a humidified incubator with 5% CO<sub>2</sub> in RPMI-1640 growth medium  
308 supplemented with 10% FBS, 100 IU/ml penicillin, 0.1 mg/ml streptomycin, 10 mmol/l L-glutamine

309 supplemented with IL2 for 48h<sup>62</sup>. Following that, CD4<sup>+</sup> T cells were treated with oxylinin 10-HOME  
310 (100 µM) or vehicle control for 48 h.

311 **Immunohistochemistry and immunocytochemistry.** Paraffin embedded breast tissue blocks  
312 were sectioned, deparaffinized and immunostained<sup>22, 39, 63</sup>. Immunohistochemical staining of the  
313 sections were performed using standard procedures using the following primary antibodies: α-  
314 CD4 antibody (abcam# ab133616; dilution 1:200), α-CD36 antibody (Abcam # ab80080, clone  
315 MF3, dilution: 1:200), α- T-bet antibody (Abcam # ab91109, clone 4B10, dilution: 1:200). To  
316 enable fluorescence detection, sections were incubated with appropriate Alexa Fluor® 488  
317 (green, Molecular probes), or Alexa Fluor® 564 (red, Molecular probes) conjugated secondary  
318 antibodies. The sections were counterstained with DAPI (Sigma). For immunocytochemistry, cells  
319 were fixed with IC fixation buffer (eBioscience), blocked with 10 percent normal goat serum  
320 (Vector Laboratories), incubated with primary and secondary antibodies and counterstained with  
321 DAPI. Mosaic images were collected using a Zeiss Axiovert 200 M, inverted fluorescence  
322 microscopy or confocal microscopy (LSM880). Image analysis was performed using Zen  
323 (Zeiss) software to quantitate fluorescence intensity (fluorescent pixels).

324 **Lipid extraction and 10-HOME quantification using LCMS.** LC-MS/MS targeted analysis from  
325 capsule and breast adipose tissue was performed. Samples were weighed and transferred to 2  
326 ml vials with 1.4 mm ceramic beads and 1 ml of water with 0.1% formic acid. The standard solution  
327 was prepared by aliquoting 1µl of each stock solution into a new tube drying the original solvent  
328 and solubilizing in 1 ml of 100% ethanol to obtain a final concentration of 1 ng/ml each. Samples  
329 were homogenized using Precellys24 tissue homogenizer (Bertin Technologies, Rockville, MD).  
330 The total volume of the homogenate was extracted with ethyl acetate in a 1:1 volume ratio.  
331 Samples were vortexed for 1 minute and centrifuged at 14,000 rpm for 10 minutes. The organic  
332 phase was collected and transferred to a new vial to be evaporated and stored at -80°C until  
333 analysis. The dried lipid extracts were reconstituted with 50 µl of methanol/water at 1:1 volume

334 ratio and submitted for targeted quantification by liquid chromatography tandem MS (LC/MS/MS).  
335 The LC column used was an Acquity UPLC BEH C18 1.7 $\mu$ m particle size - 2.1x100 mm (Waters,  
336 Milford, MA). The binary pump flow rate was set at 0.3mL/min in an Agilent UPLC (G7120A) using  
337 water and 0.1% formic acid as mobile phase A and acetonitrile and 0.1% formic acid as mobile  
338 phase B. The LC column was pre-equilibrated with 80% A for 1 min. The binary pump was set in  
339 a linear gradient to 100% B in 8 min and held for 2.50 min. It was then returned to 80% A and re-  
340 equilibrated for 4 min. Ten  $\mu$ L of the reconstituted sample was delivered to the column through a  
341 multisampler (G7167B) into a QQQ6470A triple quadrupole mass spectrometer (Agilent  
342 Technologies, San Jose, CA) equipped with ESI Jet Stream ion source. In the mass spectrometer  
343 the capillary voltage was 3500 V on the negative ion mode, the gas temperature was 325 $^{\circ}$ C, gas  
344 flow was set at 8l/min, the sheath gas heater at 250 $^{\circ}$ C and the sheath gas flow at 7 l/min. The  
345 fragmentation voltage was 100 and the cell accelerator voltage was 4 V. The MRMs (parent-  
346 fragment) for the acquisition included were 297.5->155.4 for 10-HOME and for the internal  
347 standard it was 302.4->155.4. Concentrations in ng/mg of tissue were obtained by normalizing by  
348 the dried weight of the sample homogenized and by the concentration of the deuterated internal  
349 standard. To quantify 10-HOME, calibration curves were done with 7 serial dilutions of the stock  
350 solution starting at 10 ng as the highest concentration. Data processing was carried out by using  
351 Mass Hunter (B.06.00) using software Quant and Qual.

352 **Flow cytometry analyses.** The fluorescence and light-scattering properties (forward scatter and  
353 side scatter) of the cells were determined by using BD Accuri C6. Signals from cells labeled with  
354 conjugated fluorophores were detected. The following antibodies were used for different flow  
355 cytometry analysis. PE anti-human CD183 (CXCR3) (clone G025H7, Biolegend # 353705, 2  
356  $\mu$ g/ml), PE anti-human CD194 (CCR4) (clone L291H4, Biolegend # 359412, 0.5  $\mu$ g/ml), PE anti-  
357 human CD196 (CCR6) (clone G034E3, Biolegend # 353410, 0.5  $\mu$ g/ml), FITC anti-human CD4  
358 (clone A161A1, Biolegend # 357406 , 0.5  $\mu$ g/ml), APC anti-human CD194 (CCR4) (clone L291H4,

359 Biolegend # 359407, 0.5 µg/ml), Alexa Fluor® 700 anti-human CD196 (CCR6) (clone G034E3,  
360 Biolegend # 353433, 0.5 µg/ml), PE anti-human CD36 (clone 5-271, Biolegend # 336205, 1  
361 µg/ml), FITC anti-mouse CD4 (clone GK1.5, Biolegend # 100406, 0.5 µg/ml), APC anti-mouse  
362 CD36 (clone HM36, Biolegend # 102612, 0.5 µg/ml), PE anti-mouse CD183 CD36 (clone CXCR3-  
363 173, Biolegend # 126506, 0.5 µg/ml), PE anti-mouse CD196 (clone 29-2L17, Biolegend # 129804,  
364 0.5 µg/ml), APC anti-mouse CD194 (clone 2G12, Biolegend # 131211, 0.5 µg/ml), PE anti-mouse  
365 FOXP3 (clone MF14, Biolegend # 126403, 0.5 µg/ml), PE anti-T-bet Antibody (clone 4B10,  
366 Biolegend # 644809, 0.5 µg/ml). For intracellular markers, TBET and GATA3 permeabilization  
367 was performed through True-nuclear transcription factor buffer set (Biolegend # 424401). Auto  
368 compensation was performed using samples stained with single fluorophores. Gates were set  
369 manually. BD Diva (BD Biosciences), and FlowJo softwares were used for analyses<sup>63</sup>.  
370 Logarithmic scale was used to measure cell fluorescence. Appropriate IgG control fluorescence  
371 compensation was applied to avoid false positive signals.

372 **ELISA.** Cell-free supernatants were collected and stored at -80°C. ELISAs for IFN-γ, IL4 and  
373 IL10 were performed using DuoSet kits (R&D Systems) as per manufacturer's protocol.

374 **10-HOME administration in mice.** At approximately 9 to 10 weeks of age, female mice were  
375 anesthetized with isoflurane, and five injections of 10-HOME (15 mg/kg body weight) every  
376 alternate day was made with a 27 G needle to the abdominal mammary fat pad of mice. Post-two  
377 weeks of the dose the mice were euthanized. Blood, mammary fat pad and spleen were harvested  
378 for subsequent analyses.

379 **Quantitative RT PCR.** Breast tissue was pulverized using tissue pulverizer (6770 Freezer/Mill)  
380 and total RNA was extracted using miRVana (Thermo Fisher Scientific). cDNA was made using  
381 SuperScript™ III First-Strand Synthesis System (Invitrogen) or SuperScript™ VILO™ cDNA  
382 Synthesis Kit (Invitrogen). Quantitative or real-time PCR (Sybr Green) approach was used for



383 mRNA quantification<sup>63-68</sup>. Primer sequences used in this study provided in (**Supplementary**  
384 **Table 3**).

385

### 386 **Quantification and statistical analysis**

387 The data analysis was performed using student's t-test (two-tailed) to determine significant  
388 differences. Mean, standard deviation and student paired *t*-test analysis was done using in-built  
389 function in Microsoft Excel 2010. Data are presented as mean  $\pm$  SEM (*in vivo*) or  $\pm$  SD (*in vitro*)  
390 as reported in figure legends. Comparisons among multiple groups were tested using ANOVA in-  
391 built function in GraphPad Prism 8.4.2.  $p < 0.05$  was considered statistically significant.

### 392 **ACKNOWLEDGEMENTS**

393 This work was supported by Aesthetic Surgery Education and Research Foundation (ASERF)  
394 grant to MS, Department of Defense PR200435, and American Association of Plastic Surgeons  
395 grants to AHH, the US National Institutes of Health grants NIH NR015676, U01DK119099 to GG  
396 and CKS; NIH R01GM108014, R01NS042617, R01DK125835 to CKS. The authors acknowledge  
397 Core Services for SEM at INDI Core, Indiana University Purdue University Indianapolis. We thank  
398 Metabolite Profiling Facility, Purdue University, West Lafayette. We thank Dr. Lava Timsina,  
399 Indiana University School of Medicine for his help with the statistics. We thank Dr. Allen Epstein,  
400 Keck School of Medicine, University of Southern California for his kind donation of the breast  
401 implant-associated anaplastic large cell lymphoma (BIA-ALCL), T cell line TLBR1.

### 402 **AUTHOR CONTRIBUTIONS**

403 MS, IK, and AHH conceived and designed the work. IK, REM, CKP, BWV, CRN, LS, KS, ML, JVD  
404 participated in the data acquisition. MS, REM, IK, CKP, AHH and MEK wrote the manuscript. MS,  
405 REM, CKS, GMG, MEK, BWV reviewed the manuscript.

406 **DECLARATION OF INTERESTS**

407 The authors declare no competing interests

408 **REFERENCES**

- 409 1. Safety of Silicone Breast Implants. In: S. Bondurant, V. Ernster and R. Herdman, eds.  
410 *Institute of Medicine* Washington (DC): The National Academies Press;  
411 1999(<https://doi.org/10.17226/9602>).
- 412 2. FDA Update on the Safety of Silicone Gel-Filled Breast Implants.  
413 2011;<https://www.fda.gov/media/80685/download>.
- 414 3. 2019 Plastic Surgery Statistics. 2019;[https://www.plasticsurgery.org/news/plastic-](https://www.plasticsurgery.org/news/plastic-surgery-statistics)  
415 [surgery-statistics](https://www.plasticsurgery.org/news/plastic-surgery-statistics).
- 416 4. Fryzek JP, Signorello LB, Hakelius L, Feltelius N, Ringberg A, Blot WJ, McLaughlin JK  
417 and Nyren O. Self-reported symptoms among women after cosmetic breast implant and breast  
418 reduction surgery. *Plast Reconstr Surg*. 2001;107:206-13.
- 419 5. Maijers MC, de Blok CJ, Niessen FB, van der Veldt AA, Ritt MJ, Winters HA, Kramer MH  
420 and Nanayakkara PW. Women with silicone breast implants and unexplained systemic  
421 symptoms: a descriptive cohort study. *Neth J Med*. 2013;71:534-40.
- 422 6. ASAPS. Breast Implant Illness - Frequently Asked Questions/Talking Points.  
423 [https://www.surgery.org/sites/default/files/BreastImplantIllness\\_8-21-2019\\_FINALpdf](https://www.surgery.org/sites/default/files/BreastImplantIllness_8-21-2019_FINALpdf). 2019.
- 424 7. Balk EM, Earley A, Avendano EA and Raman G. Long-Term Health Outcomes in  
425 Women With Silicone Gel Breast Implants: A Systematic Review. *Ann Intern Med*.  
426 2016;164:164-75.
- 427 8. Coroneos CJ, Selber JC, Offodile AC, 2nd, Butler CE and Clemens MW. US FDA Breast  
428 Implant Postapproval Studies: Long-term Outcomes in 99,993 Patients. *Ann Surg*. 2019;269:30-  
429 36.

- 430 9. Khoo T, Proudman S and Limaye V. Silicone breast implants and depression,  
431 fibromyalgia and chronic fatigue syndrome in a rheumatology clinic population. *Clin Rheumatol.*  
432 2019;38:1271-1276.
- 433 10. Lee IM, Cook NR, Shadick NA, Pereira E and Buring JE. Prospective cohort study of  
434 breast implants and the risk of connective-tissue diseases. *Int J Epidemiol.* 2011;40:230-8.
- 435 11. Singh N, Picha GJ, Hardas B, Schumacher A and Murphy DK. Five-Year Safety Data for  
436 More than 55,000 Subjects following Breast Implantation: Comparison of Rare Adverse Event  
437 Rates with Silicone Implants versus National Norms and Saline Implants. *Plast Reconstr Surg.*  
438 2017;140:666-679.
- 439 12. Watad A, Rosenberg V, Tiosano S, Cohen Tervaert JW, Yavne Y, Shoenfeld Y, Shalev  
440 V, Chodick G and Amital H. Silicone breast implants and the risk of autoimmune/rheumatic  
441 disorders: a real-world analysis. *Int J Epidemiol.* 2018;47:1846-1854.
- 442 13. de Boer M, Colaris M, van der Hulst R and Cohen Tervaert JW. Is explantation of  
443 silicone breast implants useful in patients with complaints? *Immunol Res.* 2017;65:25-36.
- 444 14. Peters W, Smith D, Fornasier V, Lugowski S and Ibanez D. An outcome analysis of 100  
445 women after explantation of silicone gel breast implants. *Ann Plast Surg.* 1997;39:9-19.
- 446 15. Tanne JH. FDA approves silicone breast implants 14 years after their withdrawal. *BMJ.*  
447 2006;333:1139.
- 448 16. Alijotas-Reig J, Esteve-Valverde E, Gil-Aliberas N and Garcia-Gimenez V.  
449 Autoimmune/inflammatory syndrome induced by adjuvants-ASIA-related to biomaterials:  
450 analysis of 45 cases and comprehensive review of the literature. *Immunol Res.* 2018;66:120-  
451 140.
- 452 17. Greenland S and Finkle WD. A case-control study of prosthetic implants and selected  
453 chronic diseases in Medicare claims data. *Ann Epidemiol.* 1998;8:319-26.

- 454 18. Laing TJ, Schottenfeld D, Lacey JV, Jr., Gillespie BW, Garabrant DH, Cooper BC,  
455 Heeringa SG, Alcsér KH and Mayes MD. Potential risk factors for undifferentiated connective  
456 tissue disease among women: implanted medical devices. *Am J Epidemiol.* 2001;154:610-7.
- 457 19. Møllekjær L, Friis S, McLaughlin JK, Thomsen BL, Kjoller K, Hogsted C, Winther JF,  
458 Blot WJ and Olsen JH. Connective tissue disease after hip and knee implant surgery. *Scand J*  
459 *Rheumatol.* 2001;30:82-6.
- 460 20. Signorello LB, Ye W, Fryzek JP, Blot WJ, Lipworth L, McLaughlin JK and Nyren O. A  
461 nationwide followup study of autoimmune and connective tissue disease among hip and knee  
462 implant patients. *J Long Term Eff Med Implants.* 2002;12:255-62.
- 463 21. Vyas KS and Wong LK. Detection of Biofilm in Wounds as an Early Indicator for Risk for  
464 Tissue Infection and Wound Chronicity. *Ann Plast Surg.* 2016;76:127-31.
- 465 22. Roy S, Elgharably H, Sinha M, Ganesh K, Chaney S, Mann E, Miller C, Khanna S,  
466 Bergdall VK, Powell HM, Cook CH, Gordillo GM, Wozniak DJ and Sen CK. Mixed-species  
467 biofilm compromises wound healing by disrupting epidermal barrier function. *J Pathol.*  
468 2014;233:331-343.
- 469 23. Rhoads DD, Cox SB, Rees EJ, Sun Y and Wolcott RD. Clinical identification of bacteria  
470 in human chronic wound infections: culturing vs. 16S ribosomal DNA sequencing. *BMC Infect*  
471 *Dis.* 2012;12:321.
- 472 24. Martínez E and Campos-Gómez J. Oxylipins produced by *Pseudomonas aeruginosa*  
473 promote biofilm formation and virulence. *Nat Commun.* 2016;7:13823.
- 474 25. Levan SR, Stamnes KA, Lin DL, Fujimura KE, Ownby DR, Zoratti EM, Boushey HA,  
475 Johnson CC and Lynch SV. Neonatal gut-microbiome-derived 12,13 DiHOME impedes  
476 tolerance and promotes childhood atopy and asthma. *bioRxiv.* 2018:311704.
- 477 26. Kanhere A, Hertweck A, Bhatia U, Gokmen MR, Perucha E, Jackson I, Lord GM and  
478 Jenner RG. T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific  
479 targeting of distal regulatory elements. *Nat Commun.* 2012;3:1268.

- 480 27. Skapenko A, Leipe J, Lipsky PE and Schulze-Koops H. The role of the T cell in  
481 autoimmune inflammation. *Arthritis Research & Therapy*. 2005;7:S4.
- 482 28. Zhang X, Fitzsimmons RL, Cleland LG, Ey PL, Zannettino AC, Farmer EA, Sincock P  
483 and Mayrhofer G. CD36/fatty acid translocase in rats: distribution, isolation from hepatocytes,  
484 and comparison with the scavenger receptor SR-B1. *Lab Invest*. 2003;83:317-32.
- 485 29. Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, Waldmann TA and  
486 Perera PY. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as  
487 a therapeutic modality for T-cell malignancies. *Am J Hematol*. 2017;92:892-901.
- 488 30. Oishi N, Hundal T, Phillips JL, Dasari S, Hu G, Viswanatha DS, He R, Mai M, Jacobs  
489 HK, Ahmed NH, Syrbu SI, Salama Y, Chapman JR, Vega F, Sidhu J, Bennani NN, Epstein AL,  
490 Medeiros LJ, Clemens MW, Miranda RN and Feldman AL. Molecular profiling reveals a hypoxia  
491 signature in breast implant-associated anaplastic large cell lymphoma. *Haematologica*. 2020.
- 492 31. Kostakioti M, Hadjifrangiskou M and Hultgren SJ. Bacterial biofilms: development,  
493 dispersal, and therapeutic strategies in the dawn of the postantibiotic era. *Cold Spring Harb*  
494 *Perspect Med*. 2013;3:a010306.
- 495 32. Parsonnet J. Bacterial infection as a cause of cancer. *Environ Health Perspect*.  
496 1995;103 Suppl 8:263-8.
- 497 33. Mousa JJ, Yang Y, Tomkovich S, Shima A, Newsome RC, Tripathi P, Oswald E, Bruner  
498 SD and Jobin C. MATE transport of the E. coli-derived genotoxin colibactin. *Nat Microbiol*.  
499 2016;1:15009.
- 500 34. Tomkovich S, Yang Y, Winglee K, Gauthier J, Muhlbauer M, Sun X, Mohamadzadeh M,  
501 Liu X, Martin P, Wang GP, Oswald E, Fodor AA and Jobin C. Locoregional Effects of Microbiota  
502 in a Preclinical Model of Colon Carcinogenesis. *Cancer Res*. 2017;77:2620-2632.
- 503 35. Cappelli G, Tetta C and Canaud B. Is biofilm a cause of silent chronic inflammation in  
504 haemodialysis patients? A fascinating working hypothesis. *Nephrol Dial Transplant*.  
505 2005;20:266-70.

- 506 36. Zhao G, Usui ML, Lippman SI, James GA, Stewart PS, Fleckman P and Olerud JE.  
507 Biofilms and Inflammation in Chronic Wounds. *Adv Wound Care (New Rochelle)*. 2013;2:389-  
508 399.
- 509 37. Hu H, Johani K, Almatroudi A, Vickery K, Van Natta B, Kadin ME, Brody G, Clemens M,  
510 Cheah CY, Lade S, Joshi PA, Prince HM and Deva AK. Bacterial Biofilm Infection Detected in  
511 Breast Implant-Associated Anaplastic Large-Cell Lymphoma. *Plast Reconstr Surg*.  
512 2016;137:1659-69.
- 513 38. Barki KG, Das A, Dixith S, Ghatak PD, Mathew-Steiner S, Schwab E, Khanna S,  
514 Wozniak DJ, Roy S and Sen CK. Electric Field Based Dressing Disrupts Mixed-Species  
515 Bacterial Biofilm Infection and Restores Functional Wound Healing. *Ann Surg*. 2019;269:756-  
516 766.
- 517 39. Roy S, Santra S, Das A, Dixith S, Sinha M, Ghatak S, Ghosh N, Banerjee P, Khanna S,  
518 Mathew-Steiner S, Ghatak PD, Blackstone BN, Powell HM, Bergdall VK, Wozniak DJ and Sen  
519 CK. Staphylococcus aureus Biofilm Infection Compromises Wound Healing by Causing  
520 Deficiencies in Granulation Tissue Collagen. *Ann Surg*. 2020;271:1174-1185.
- 521 40. James GA, Boegli L, Hancock J, Bowersock L, Parker A and Kinney BM. Bacterial  
522 Adhesion and Biofilm Formation on Textured Breast Implant Shell Materials. *Aesthetic Plast*  
523 *Surg*. 2019;43:490-497.
- 524 41. Urbaniak C, Cummins J, Brackstone M, Macklaim JM, Gloor GB, Baban CK, Scott L,  
525 O'Hanlon DM, Burton JP, Francis KP, Tangney M and Reid G. Microbiota of human breast  
526 tissue. *Appl Environ Microbiol*. 2014;80:3007-14.
- 527 42. Brandwein M, Steinberg D and Meshner S. Microbial biofilms and the human skin  
528 microbiome. *NPJ Biofilms Microbiomes*. 2016;2:3.
- 529 43. Cohen JB, Carroll C, Tenenbaum MM and Myckatyn TM. Breast Implant-Associated  
530 Infections: The Role of the National Surgical Quality Improvement Program and the Local  
531 Microbiome. *Plast Reconstr Surg*. 2015;136:921-9.

- 532 44. Walker JN, Poppler LH, Pinkner CL, Hultgren SJ and Myckatyn TM. Establishment and  
533 Characterization of Bacterial Infection of Breast Implants in a Murine Model. *Aesthet Surg J*.  
534 2020;40:516-528.
- 535 45. Song JH, Kim YS, Jung BK, Lee DW, Song SY, Roh TS and Lew DH. Salvage of  
536 Infected Breast Implants. *Arch Plast Surg*. 2017;44:516-522.
- 537 46. Brindle CT, Porter S, Bijlani K, Arumugam S, Matias R, Najafi R and Fisher J.  
538 Preliminary Results of the Use of a Stabilized Hypochlorous Acid Solution in the Management of  
539 *Ralstonia Pickettii* Biofilm on Silicone Breast Implants. *Aesthet Surg J*. 2018;38:S52-S61.
- 540 47. Azeredo J, Azevedo NF, Briandet R, Cerca N, Coenye T, Costa AR, Desvaux M, Di  
541 Bonaventura G, Hebraud M, Jaglic Z, Kacaniova M, Knochel S, Lourenco A, Mergulhao F,  
542 Meyer RL, Nychas G, Simoes M, Tresse O and Sternberg C. Critical review on biofilm methods.  
543 *Crit Rev Microbiol*. 2017;43:313-351.
- 544 48. Swearingen MC, DiBartola AC, Dusane D, Granger J and Stoodley P. 16S rRNA  
545 analysis provides evidence of biofilms on all components of three infected periprosthetic knees  
546 including permanent braided suture. *Pathog Dis*. 2016;74.
- 547 49. Lee M, Ponraja G, McLeod K and Chong S. Breast Implant Illness: A Biofilm Hypothesis.  
548 *Plast Reconstr Surg Glob Open*. 2020;8:e2755.
- 549 50. Chajes V, Niyongabo T, Lanson M, Fignon A, Couet C and Bognoux P. Fatty-acid  
550 composition of breast and iliac adipose tissue in breast-cancer patients. *Int J Cancer*.  
551 1992;50:405-8.
- 552 51. Zhu ZR, Agren J, Mannisto S, Pietinen P, Eskelinen M, Syrjanen K and Uusitupa M.  
553 Fatty acid composition of breast adipose tissue in breast cancer patients and in patients with  
554 benign breast disease. *Nutr Cancer*. 1995;24:151-60.
- 555 52. Kotsougiani D, Pioch M, Prior B, Heppert V, Hansch GM and Wagner C. Activation of T  
556 Lymphocytes in Response to Persistent Bacterial Infection: Induction of CD11b and of Toll-Like  
557 Receptors on T Cells. *Int J Inflam*. 2010;2010:526740.

- 558 53. Gonzalez JF, Hahn MM and Gunn JS. Chronic biofilm-based infections: skewing of the  
559 immune response. *Pathog Dis*. 2018;76.
- 560 54. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population  
561 of nonspecific cells: a tale of smart bombs and the infantry. *Proc Natl Acad Sci U S A*.  
562 1996;93:2253-6.
- 563 55. Nicholson LB and Kuchroo VK. Manipulation of the Th1/Th2 balance in autoimmune  
564 disease. *Curr Opin Immunol*. 1996;8:837-42.
- 565 56. Liblau RS, Singer SM and McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis  
566 of organ-specific autoimmune diseases. *Immunol Today*. 1995;16:34-8.
- 567 57. Raphael I, Nalawade S, Eagar TN and Forsthuber TG. T cell subsets and their signature  
568 cytokines in autoimmune and inflammatory diseases. *Cytokine*. 2015;74:5-17.
- 569 58. Osthues T and Sisignano M. Oxidized Lipids in Persistent Pain States. *Front Pharmacol*.  
570 2019;10:1147.
- 571 59. Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P and Giannopoulos K. The  
572 Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. *Arch Immunol Ther Exp*  
573 *(Warsz)*. 2015;63:435-49.
- 574 60. Deng B, Ghatak S, Sarkar S, Singh K, Das Ghatak P, Mathew-Steiner SS, Roy S,  
575 Khanna S, Wozniak DJ, McComb DW and Sen CK. Novel Bacterial Diversity and Fragmented  
576 eDNA Identified in Hyperbiofilm-Forming *Pseudomonas aeruginosa* Rugose Small Colony  
577 Variant. *iScience*. 2020;23:100827.
- 578 61. Shen W, Falahati R, Stark R, Leitenberg D and Ladisch S. Modulation of CD4 Th cell  
579 differentiation by ganglioside GD1a in vitro. *J Immunol*. 2005;175:4927-34.
- 580 62. Ganusov VV, Milutinovic D and De Boer RJ. IL-2 regulates expansion of CD4+ T cell  
581 populations by affecting cell death: insights from modeling CFSE data. *J Immunol*.  
582 2007;179:950-7.



- 583 63. Sinha M, Sen CK, Singh K, Das A, Ghatak S, Rhea B, Blackstone B, Powell HM,  
584 Khanna S and Roy S. Direct conversion of injury-site myeloid cells to fibroblast-like cells of  
585 granulation tissue. *Nat Commun.* 2018;9:936.
- 586 64. Das A, Ganesh K, Khanna S, Sen CK and Roy S. Engulfment of apoptotic cells by  
587 macrophages: a role of microRNA-21 in the resolution of wound inflammation. *J Immunol.*  
588 2014;192:1120-9.
- 589 65. Das A, Ghatak S, Sinha M, Chaffee S, Ahmed NS, Parinandi NL, Wohleb ES, Sheridan  
590 JF, Sen CK and Roy S. Correction of MFG-E8 Resolves Inflammation and Promotes Cutaneous  
591 Wound Healing in Diabetes. *J Immunol.* 2016;196:5089-100.
- 592 66. Ganesh K, Das A, Dickerson R, Khanna S, Parinandi NL, Gordillo GM, Sen CK and Roy  
593 S. Prostaglandin E(2) induces oncostatin M expression in human chronic wound macrophages  
594 through Axl receptor tyrosine kinase pathway. *J Immunol.* 2012;189:2563-73.
- 595 67. Khanna S, Biswas S, Shang Y, Collard E, Azad A, Kauh C, Bhasker V, Gordillo GM, Sen  
596 CK and Roy S. Macrophage dysfunction impairs resolution of inflammation in the wounds of  
597 diabetic mice. *PLoS One.* 2010;5:e9539.
- 598 68. Das A, Datta S, Roche E, Chaffee S, Jose E, Shi L, Grover K, Khanna S, Sen CK and  
599 Roy S. Novel mechanisms of Collagenase Santyl Ointment (CSO) in wound macrophage  
600 polarization and resolution of wound inflammation. *Sci Rep.* 2018;8:1696.


601

602

603

604

605



**Figure 1**

## Figure 1. Bacterial Biofilm in Implant-Associated with BII

**(A)** Schematic presentation of the bacterial biofilm association with breast implant illness (BII)

**(B)** Breast implant isolated from a subject


**(C)** Capsule associated with breast implant of the subject shown in (B)

**(D)** Increased abundance of bacterial biofilm from the implant-associated capsule of BII compared to non BII subjects as determined through scanning electron microscopy. Zoomed insets of region of interest (ROI) dotted yellow square shown. n=10 non-BII subjects, n=25 BII subjects.

**(E-F)** **E**, Increased abundance of bacterial biofilm as measured through wheat germ agglutinin (WGA) assay in the capsules of BII subjects compared to the non-BII capsules. **F**, quantification of biofilm aggregates using WGA staining. Data presented as mean  $\pm$  SEM, n=7 non-BII, n=7 BII

**(G-I)** 16S rRNA NGS based bacterial typing from the breast tissues of **G**, normal; **H**, non-BII and **I**, BII subjects. Top five bacterial species in each group represented. Absolute values of subject samples associated with a bacterial species is provided in parenthesis n=8 (normal), n=14 (non-BII), n=46 (BII)

**(J)** Increased abundance of biofilm forming *Staphylococcus epidermidis* in implant-associated breast tissues of BII subjects. Percentage of Patients with *Cutibacterium acnes* and *Staphylococcus epidermidis* provided above the individual bars. n=8 (normal), n=14 (non-BII), n=46 (BII)



**Figure 2**

## Figure 2 .Increased Abundance of Biofilm Derived 10-HOME in BII Subjects


**(A)** Schematic of formation of 10-HOME from oleic acid

**(B-D)** Increased abundance of 10-HOME in implant associated tissue of BII subjects. **B.** Chromatograms of 10-HOME from non-BII and BII using LC-MS/MS targeted analyses. **C.** Data presented as mean  $\pm$  SEM, n=6 (non-BII), n=17 (BII). **D.** Receiver operating characteristic (ROC) curve analysis to determine specificity and sensitivity of 10-HOME detection.

**(E)** Increased abundance of bacteria associated with 10-HOME detected from the implant associated tissue of BII subjects.

**(F)** Increased abundance of *Staphylococcus epidermidis* associated with 10-HOME detected from the implant associated tissue of BII subjects.

**(G)** Synthesis of 10-HOME by *S. epidermidis in vitro* upon using oleic acid as carbon source. Gas chromatography- mass spectrometry analyses for detection of 10-HOME. **i-** oleic acid standard, **ii-** 10-HOME standard, **iii-** *S.epidermidis* with glucose as carbon source, **iv-** *S.epidermidis* with Oleic acid as carbon source, **v-** quantification of 10-HOME abundance. n=4




**Figure 3**

### **Figure 3. Abundance of CD4+ Th1 Cells in Implant Associated Tissue of BII Subjects**

**(A)** Increased expression of T-BET (transcription factor for Th1 subtype) in breast tissue associated with BII subjects compared to non-BII breast tissue. Breast tissue immuno-stained with anti-CD4 (red) antibody, anti-T-BET (green) and DAPI (blue). Intensity of TBET for the two groups, colocalization of CD4 and T-BET depicted increased abundance of CD4<sup>+</sup> TBET<sup>+</sup> cells in the breast tissues of BII subjects. Data presented as mean  $\pm$  SEM, (n=7). Scale bar = 20  $\mu$ m

**(B)** Increased expression of CD36 (fatty acyl translocase) in breast tissue associated with BII subjects compared to non-BII breast tissue. Breast tissue immuno-stained with anti-CD4 (red) antibody, anti-CD36 (green) and DAPI (blue). Intensity of CD36 for the two groups, colocalization of CD4 and CD36 depicted increased abundance of CD4<sup>+</sup> CD36<sup>+</sup> cells in the breast tissues of BII subjects. Data presented as mean  $\pm$  SEM, (n=7). Scale bar = 20  $\mu$ m

**(C)** Elevated Th1 subtype in the peripheral blood of BII subjects. Flow cytometry analyses of peripheral blood of subjects stained with anti-CD4 (FITC) and anti-CD183 (PE). Representative flow plots. (i) non-BII (ii) BII (iii) histogram with isotype control for CD183 (iv) % of CD4<sup>+</sup> CD183<sup>+</sup> T cells. Data presented as mean  $\pm$  SEM, (n=5-11).





#### **Figure 4. Oxylinin 10-HOME Polarizes Naïve CD4<sup>+</sup> T Cells to Th1 Subtype *in vitro***

**(A)** Increased expression of CD36 in naïve CD4<sup>+</sup> T cells treated with 100 µm of 10-HOME compared to vehicle post-48h. T cells were immuno-stained with anti-CD4 (red) antibody, anti- CD36 (green) and DAPI (blue). Intensity of CD36 quantified for the two groups. Colocalization of CD4 and TBET depicted increased abundance of CD4<sup>+</sup> CD36<sup>+</sup> cells in the breast tissues of BII subjects. Data presented as mean ± SD, (n=6). Scale bar = 10 µm

**(B)** Elevated CD36 in the 10-HOME treated naïve T cells. Flow cytometry analyses of treated cells stained with anti-CD4 (FITC) and anti-CD36 (APC). Representative flow plots. (i) vehicle treated (ii) 10-HOME treated (iii) histogram with isotype control for CD36 (iv) % of CD4<sup>+</sup> CD36<sup>+</sup> T cells. Data presented as mean ± SD, (n=7).

**(C)** Increased expression of T-BET in naïve CD4<sup>+</sup> T cells treated with 100 µm of 10-HOME compared to vehicle post-48h. T cells were immuno-stained with anti-CD4 (red) antibody, anti- TBET (green) and DAPI (blue). Intensity of TBET quantified for the two groups. Colocalization of CD4 and TBET depicted increased abundance of CD4<sup>+</sup> TBET<sup>+</sup> cells in the breast tissues of BII subjects. Data presented as mean ± SD, (n=6). Scale bar = 10 µm

**(D)** Elevated Th1 subtype (CD183<sup>+</sup>) in the 10-HOME treated naïve CD4<sup>+</sup> T cells. Flow cytometry analyses of treated cells stained with anti-CD4 (FITC) and anti-CD183 (PE). Representative flow plots. (i) vehicle treated (ii) 10-HOME treated (iii) histogram with isotype control for CD183 (iv) % of CD4<sup>+</sup> CD183<sup>+</sup>. Data presented as mean ± SD, (n=7).


**(E)** Increased expression of Th1 secreted pro-inflammatory cytokine IFN-γ in the 10-HOME treated naïve CD4<sup>+</sup> T cells as measured through ELISA. Data presented as mean ± SD (n=7).

**(F-G)** No significant change in the cytokines IL4 and IL10 following 10-HOME treatment of naïve CD4<sup>+</sup> T cells as measured through ELISA, Data presented as mean ± SD, (n=8).

**(H-I)** Increased expression of (H) CD36 (I) T-BET in 10-HOME treated naïve T cells as measured through quantitative real time PCR. Data presented as mean ± SD, (n=6).


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

**A**




**B**


**i vehicle**



**ii 10-HOME**




**iii**




**C**


**i vehicle**



**ii 10-HOME**



**iii**



**Figure 5**

## **Figure 5. Elevated CD4<sup>+</sup> Th1 in Peripheral Blood of Mice Administered with 10-HOME**

- (A)** Schematic representation of injection of 10-HOME in the abdominal mammary fat pad of mice.
- (B)** Elevated CD4<sup>+</sup> Th1 subtype in the blood of mice injected with 10-HOME. Flow cytometry analyses of blood of mice stained with anti-CD4 (FITC) and anti-CD183 (PE). Representative flow plots. (i) Vehicle treated (ii) 10-HOME treated (iii) % of CD4<sup>+</sup> CD183<sup>+</sup> T cells. Data presented as mean  $\pm$  SEM, (n=4-6 mice).
- (C)** Unaltered CD4<sup>+</sup> Th2 subtype in the blood of mice injected with 10-HOME. Flow cytometry analyses of blood of mice stained with anti-CD4 (FITC) and anti-CD194 (PE). Representative flow plots. (i) Vehicle treated (ii) 10-HOME treated (iii) % of CD4<sup>+</sup> CD194<sup>+</sup> T cells. Data presented as mean  $\pm$  SEM, (n=4-6 mice).